Edwards Lifesciences Corporation $EW Shares Sold by Caisse Des Depots ET Consignations

Key Points

• Caisse Des Depots ET Consignations trimmed its stake in Edwards Lifesciences by 19.4%, selling 12,427 shares and leaving 51,766 shares valued at about $4.41 million per the latest 13F filing.
• Company insiders sold a combined 86,058 shares (~$7.12 million) over the last quarter, including CFO Scott B. Ullem (13,000 shares) and VP Donald E. Bobo Jr. (24,000 shares), leaving insiders with 0.31% ownership.
• Edwards beat the quarter (EPS $0.78 vs. $0.73 est.) with revenue up 16.7% YoY, issued FY2026 guidance of 2.95–3.05 EPS, and holds a consensus analyst rating of Moderate Buy with a $95.65 target.

Caisse Des Depots ET Consignations cut its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 19.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,766 shares of the medical research company's stock after selling 12,427 shares during the period. Caisse Des Depots ET Consignations' holdings in Edwards Lifesciences were worth $4,413,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company's stock valued at $5,472,147,000 after buying an additional 365,581 shares in the last quarter. Wellington Management Group LLP raised its stake in Edwards Lifesciences by 4.9% in the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company's stock valued at $1,617,959,000 after buying an additional 977,933 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock valued at $1,478,425,000 after buying an additional 1,423,365 shares in the last quarter. Jennison Associates LLC raised its stake in Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock valued at $1,085,574,000 after buying an additional 2,287,783 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock valued at $434,318,000 after buying an additional 4,108,270 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $84.08 on Friday. The stock's 50-day moving average is $82.08 and its two-hundred day moving average is $82.41. The firm has a market cap of $48.47 billion, a price-to-earnings ratio of 44.72, a PEG ratio of 2.10 and a beta of 0.87. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter last year, the company posted $0.64 earnings per share. The business's quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 13,000 shares of the firm's stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares of the company's stock, valued at $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm's stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total value of $2,012,160.00. Following the transaction, the vice president directly owned 21,266 shares in the company, valued at approximately $1,782,941.44. This represents a 53.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 86,058 shares of company stock valued at $7,118,636 over the last quarter. 0.31% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on EW. TD Cowen upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Friday, January 9th. Truist Financial set a $90.00 price objective on Edwards Lifesciences and gave the stock a "hold" rating in a report on Friday, April 24th. Piper Sandler reaffirmed an "overweight" rating and set a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the stock an "outperform" rating in a report on Monday, April 13th. Finally, Robert W. Baird raised their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a "neutral" rating in a report on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $95.65.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.